Article
Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma.
Nature communications - 1 Mar 2022
Smith Lorey K, Parmenter Tiffany, Kleinschmidt Margarete, Kusnadi Eric P, Kang Jian, Martin Claire A, Lau Peter, Patel Riyaben, Lorent Julie, Papadopoli David, Trigos Anna, Ward Teresa, Rao Aparna D, Lelliott Emily J, Sheppard Karen E, Goode David, Hicks Rodney J, Tiganis Tony, Simpson Kaylene J, Larsson Ola, Blythe Benjamin, Cullinane Carleen, Wickramasinghe Vihandha O, Pearson Richard B, McArthur Grant A
Abstract excerpt
Despite the success of therapies targeting oncogenes in cancer, clinical outcomes are limited by residual disease that ultimately results in relapse. This residual disease is often characterized by non-genetic adaptive resistance, that in melanoma is characterised by altered metabolism. Here, we examine how targeted therapy reprograms metabolism in BRAF-mutant melanoma cells using a genome-wide RNA interference...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.